Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant adeno-associated virus with Slc26a9
- Development stage
- Preclinical
- Lead developer
- Zunyi Medical University Affiliated Hospital
- Modality
- Gene Therapies
01
Overview
Recombinant adeno-associated virus with Slc26a9 (rAAV-Slc26a9) is an investigational gene therapy designed to overexpress solute carrier family 26 member 9 (Slc26a9), a multifunctional anion transporter and Cl- uniporter highly expressed in the gastric mucosa. Developed by researchers at the Affiliated Hospital of Zunyi Medical University, rAAV-Slc26a9 is being evaluated for the treatment of portal hypertensive gastropathy (PHG). In preclinical models, delivery of rAAV-Slc26a9 attenuates endoplasmic reticulum (ER) stress-mediated, mitochondria-dependent apoptotic signaling in gastric epithelial cells, thereby protecting the gastric mucosal defense barrier and reversing mucosal damage.
- Other names
- rAAV Slc26a9rAAV-SLC26A9rAAV-SLC-26A9rAAV-SLC 26A9recombinant adeno-associated virus with SLC26A9
02
Targets
SLC superfamily (Solute carrier superfamily)
Beyond the preview
Go deeper on recombinant adeno-associated virus with Slc26a9.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant adeno-associated virus with Slc26a9.